To determine the clinical predictive value of EMP3 expression, we incorporated factors, including age, sex, WHO grade, expression of Ki67 and PHH3, mutant status of P53, IDH1, and ATRX, methylation level of MGMT, and especially, EMP3 levels of 1013 glioma patients, into the Cox regression model. This evidence concerns the gene TP53 and glioma.